Status: current, Primitive. Date: 31-Jan 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3510268014 | Epidermal growth factor receptor antagonist | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 4589747018 | Epidermal growth factor receptor inhibitor | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 4589748011 | EGFR (epidermal growth factor receptor) inhibitor | en | Synonym | Active | Case sensitive | SNOMED CT core |
| 4589749015 | Epidermal growth factor receptor inhibitor (disposition) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Epidermal growth factor receptor antagonist | Is a | Protein kinase inhibitor | true | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Is a | Receptor antagonist | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Gefitinib | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Erlotinib hydrochloride | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Erlotinib | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Lapatinib | Has disposition | False | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Lapatinib ditosylate | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Vandetanib | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Lapatinib ditosylate monohydrate | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Human epidermal growth factor receptor 2 inhibitor | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Amivantamab | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Cetuximab | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Epidermal growth factor receptor antagonist | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Panitumumab | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Necitumumab | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Osimertinib | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Osimertinib mesilate | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Nimotuzumab | Has disposition | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some |
Reference Sets
Qualifier value foundation reference set
FHIR